About Synsight
Synsight is a Healthcare company based in Orsay (France) founded in 2013, and was acquired by Iktos in July 2024. Services in molecular modeling, bioinformatics, and structural biology are provided. Synsight offers products and services including Screening Technology and Discovery Platform. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Its legal entity is SYNSIGHT SAS.
Company details
Synsight offers services for molecular modeling, bioinformatics and structural biology. The company uses advanced virtual screening to find hits for the desired biological target among its database of 10 million compounds, or to find biological targets for the small molecule. In addition, Synsight also offers services that predict toxicity and efficacy of the molecule and for NMR-based structural elucidation of small molecules, peptides and proteins.
- Headquarters Orsay, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website synsight.net/home
- Social LinkedIn X Instagram
- Acquired by Iktos (Jul 2024)
- Legal Name Synsight Sas
Products & Services of Synsight
Synsight offers a comprehensive portfolio of products and services, including Screening Technology and Discovery Platform.
Enables development of RNA-targeting drugs using AI and imaging.
Facilitates large-scale data analysis for drug candidates.
Investors in Synsight
Synsight has secured backing from 1 investor. Prominent investors backing the company include Iktos.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Artificial intelligence is applied to de novo drug design processes. | 2016 | iktos.ai | Paris, France |
Investor details for Synsight
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Synsight
2 dated milestones of Synsight across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Synsight is founded.
- Exit Acquired by Iktos.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synsight
Complete news archive for Synsight
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synsight
Synsight was founded in 2013.
Synsight is headquartered in Orsay, France. It is registered at Orsay, Essonne, France.
Synsight offers services for molecular modeling, bioinformatics and structural biology. The company uses advanced virtual screening to find hits for the desired biological target among its database of 10 million compounds, or to find biological targets for the small molecule. In addition, Synsight also offers services that predict toxicity and efficacy of the molecule and for NMR-based structural elucidation of small molecules, peptides and proteins.
Synsight offers Screening Technology and Discovery Platform.
Synsight has 1 investor. Key investors include Iktos.
Synsight operates through Synsight Sas.
Yes. Synsight was acquired by Iktos in July 2024.